ID23546A - Formulasi-formulasi ziprasidon - Google Patents

Formulasi-formulasi ziprasidon

Info

Publication number
ID23546A
ID23546A IDP990571D ID990571D ID23546A ID 23546 A ID23546 A ID 23546A ID P990571 D IDP990571 D ID P990571D ID 990571 D ID990571 D ID 990571D ID 23546 A ID23546 A ID 23546A
Authority
ID
Indonesia
Prior art keywords
ziprasidon
formulations
ziprasidon formulations
Prior art date
Application number
IDP990571D
Other languages
English (en)
Inventor
Frank Robert Busch
Angela Carol Gatlin Hausberger
Bijan Rasadi
Daniel Ray Arenson
Original Assignee
Pfizer Prod Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=22216447&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ID23546(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Pfizer Prod Inc filed Critical Pfizer Prod Inc
Publication of ID23546A publication Critical patent/ID23546A/id

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1682—Processes
    • A61K9/1688—Processes resulting in pure drug agglomerate optionally containing up to 5% of excipient
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4858—Organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0087—Galenical forms not covered by A61K9/02 - A61K9/7023
    • A61K9/0095—Drinks; Beverages; Syrups; Compositions for reconstitution thereof, e.g. powders or tablets to be dispersed in a glass of water; Veterinary drenches

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biomedical Technology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Organic Chemistry (AREA)
  • Psychiatry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Agricultural Chemicals And Associated Chemicals (AREA)
  • Detergent Compositions (AREA)
  • Feeding Of Articles By Means Other Than Belts Or Rollers (AREA)
  • Polyamides (AREA)
IDP990571D 1998-06-15 1999-06-14 Formulasi-formulasi ziprasidon ID23546A (id)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US8922998P 1998-06-15 1998-06-15

Publications (1)

Publication Number Publication Date
ID23546A true ID23546A (id) 2000-05-04

Family

ID=22216447

Family Applications (1)

Application Number Title Priority Date Filing Date
IDP990571D ID23546A (id) 1998-06-15 1999-06-14 Formulasi-formulasi ziprasidon

Country Status (44)

Country Link
US (1) US6150366A (id)
EP (1) EP0965343B1 (id)
JP (2) JP3441676B2 (id)
KR (1) KR100338915B1 (id)
CN (1) CN1307994C (id)
AP (1) AP1216A (id)
AR (1) AR015553A1 (id)
AT (1) ATE240732T1 (id)
AU (1) AU753820B2 (id)
BG (1) BG64691B1 (id)
BR (1) BR9902268A (id)
CA (1) CA2274338C (id)
CO (1) CO5070579A1 (id)
CY (1) CY2003002I1 (id)
CZ (1) CZ297954B6 (id)
DE (1) DE69908021T2 (id)
DK (1) DK0965343T3 (id)
EA (1) EA002223B1 (id)
ES (1) ES2197581T3 (id)
GT (1) GT199900080A (id)
HN (1) HN1999000089A (id)
HR (1) HRP990193B1 (id)
HU (1) HU226487B1 (id)
ID (1) ID23546A (id)
IL (1) IL130424A (id)
IS (1) IS2182B (id)
MA (1) MA26647A1 (id)
MY (1) MY121397A (id)
NO (1) NO316713B1 (id)
NZ (1) NZ336271A (id)
OA (1) OA11064A (id)
PA (1) PA8475601A1 (id)
PE (1) PE20000632A1 (id)
PL (2) PL195606B1 (id)
PT (1) PT965343E (id)
RS (1) RS49611B (id)
SG (1) SG77243A1 (id)
SI (1) SI0965343T1 (id)
SK (1) SK286245B6 (id)
TR (1) TR199901379A2 (id)
TW (1) TW590774B (id)
UA (1) UA59383C2 (id)
UY (1) UY25649A1 (id)
ZA (1) ZA993938B (id)

Families Citing this family (66)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20080113025A1 (en) * 1998-11-02 2008-05-15 Elan Pharma International Limited Compositions comprising nanoparticulate naproxen and controlled release hydrocodone
IL145950A0 (en) * 1999-05-27 2002-07-25 Pfizer Prod Inc Ziprasidone suspension
US7175855B1 (en) 1999-05-27 2007-02-13 Pfizer Inc. Ziprasidone suspension
US10179130B2 (en) 1999-10-29 2019-01-15 Purdue Pharma L.P. Controlled release hydrocodone formulations
EP2295043A1 (en) 1999-10-29 2011-03-16 Euro-Celtique S.A. Controlled release hydrocodone formulations
AU2002227383B2 (en) 2000-10-30 2004-07-08 Euro-Celtique S.A. Controlled release hydrocodone formulations
US20040048876A1 (en) * 2002-02-20 2004-03-11 Pfizer Inc. Ziprasidone composition and synthetic controls
UY27668A1 (es) * 2002-02-20 2003-10-31 Pfizer Prod Inc Composición de ziprasidona y controles sintéticos
AU2003231788B2 (en) * 2002-05-17 2008-09-11 Duke University Method for treating obesity
US7488729B2 (en) * 2002-12-04 2009-02-10 Dr. Reddy's Laboratories Limited Polymorphic forms of ziprasidone and its hydrochloride salt and process for preparation thereof
WO2004050655A1 (en) * 2002-12-04 2004-06-17 Dr. Reddy's Laboratories Limited Polymorphic forms of ziprasidone and its hydrochloride
US20050143396A1 (en) * 2003-04-11 2005-06-30 Hertero Drugs Limited Novel crystalline forms of ziprasidone hydrochloride
KR101167579B1 (ko) * 2003-04-29 2012-07-27 오렉시젠 세러퓨틱스 인크. 체중감량용 조성물
US7678799B2 (en) * 2003-06-03 2010-03-16 Teva Pharmaceutical Industries Ltd. Crystalline ziprasidone HCl and processes for preparation thereof
US20050049295A1 (en) * 2003-06-12 2005-03-03 Dr. Reddy's Laboratories Limited Process for the preparation of 5-(2-(4-(1,2-benzisothiazol-3-yl)-1piperazinyl) ethyl)-6-chloro-1, 3-dihydro-2h-indol-2-one hydrochloride (ziprasidone hydrochloride) and its intermediate
KR20060115350A (ko) * 2003-09-02 2006-11-08 화이자 프로덕츠 인크. 지프라시돈의 지속 방출형 투여 형태
CA2543805A1 (en) * 2003-10-24 2005-05-06 Gideon Pilarsky Processes for preparation of ziprasidone
AU2003285600A1 (en) * 2003-11-28 2005-06-24 Siddiqui Mohammed Jaweed Mukarram Process for the preparing ziprasidone monohydrochloride hydrate
JP2007514001A (ja) * 2003-12-18 2007-05-31 テバ ファーマシューティカル インダストリーズ リミティド ジプラシドン塩基の多形形態ｂ２
EP1703898A2 (en) * 2003-12-31 2006-09-27 Alpharma, Inc. Ziprasidone formulations
BRPI0506829A (pt) * 2004-01-13 2007-05-29 Univ Duke composições de anticonvulsivo e droga antipsicótica e métodos para sua utilização para afetar perda de peso
US7713959B2 (en) * 2004-01-13 2010-05-11 Duke University Compositions of an anticonvulsant and mirtazapine to prevent weight gain
ATE451367T1 (de) * 2004-02-27 2009-12-15 Ranbaxy Lab Ltd Verfahren zur herstellung von ziprasidon
MXPA06012685A (es) * 2004-05-03 2007-01-16 Univ Duke Composiciones para afectar la perdida de peso.
EP1744750A2 (en) * 2004-05-06 2007-01-24 Sandoz AG Pharmaceutical composition comprising hydrophobic drug having improved solubility
CA2467538C (en) * 2004-05-14 2010-08-24 Apotex Pharmachem Inc. New amorphous ziprasidone hydrochloride (5-[2-[4-(1,2-benzisothiazol-3-yl)-1-piperazinyl]ethyl]-6-chloro-1,3-dihydro-2h-indol-2-one hydrochloride) and processes to produce the same
EP1753400A4 (en) * 2004-06-11 2012-11-28 Reddys Lab Ltd Dr PHARMACEUTICAL FOR ZIPRASIDONE
CA2471219A1 (en) * 2004-06-14 2005-12-14 Apotex Pharmachem Inc. Improved preparation of an anhydrate form of 5-[2-[4-(1,2-benzisothiazol-3-yl)-1-piperazinyl]ethyl]-6-chloro-1,3-dihydro-2h-indol-2-one hydrochloride (ziprasidone hydrochloride)
US9044503B2 (en) * 2004-08-27 2015-06-02 University Of Kentucky Research Foundation Amyloid peptide inactivating enzyme to treat alzheimer's disease peripherally
JP2008511607A (ja) 2004-08-31 2008-04-17 ファイザー・プロダクツ・インク 低溶解性薬物および重合体を含む医薬投与剤形
EP2623095A1 (en) * 2004-11-16 2013-08-07 Elan Pharma International Limited Injectable nanoparticulate olanzapine formulations
WO2006085168A2 (en) * 2005-01-07 2006-08-17 Ranbaxy Laboratories Limited Solid oral dosage forms of ziprasidone containing colloidal silicone dioxide
US7749529B2 (en) * 2005-02-08 2010-07-06 Ash Access Technology, Inc. Catheter lock solution comprising citrate and a paraben
CA2593497A1 (en) * 2005-02-11 2006-08-17 Judith Aronhime Amorphous ziprasidone mesylate
ITMI20050346A1 (it) 2005-03-07 2006-09-08 Dipharma Spa Forma solida di ziprasidone cloridrato
CA2500667C (en) * 2005-03-11 2013-01-15 Apotex Pharmachem Inc. Preparation of acid addition salts of ziprasidone and intermediates thereof by solid phase-gas phase reactions
EP1858891A2 (en) * 2005-03-14 2007-11-28 Teva Pharmaceutical Industries Ltd. Crystalline forms of ziprasidone mesylate
EP1858892A1 (en) * 2005-03-14 2007-11-28 Teva Pharmaceutical Industries Ltd Anhydrous ziprasidone mesylate and a process for its preparation
US20080305161A1 (en) * 2005-04-13 2008-12-11 Pfizer Inc Injectable depot formulations and methods for providing sustained release of nanoparticle compositions
CA2605153A1 (en) * 2005-04-13 2006-10-19 Jaymin Chandrakant Shah Injectable depot formulations and methods for providing sustained release of nanoparticle compositions
CN101198323A (zh) * 2005-04-22 2008-06-11 惠氏公司 用于治疗或预防精神障碍的治疗组合
SI1884242T1 (sl) 2005-05-26 2013-07-31 Dainippon Sumitomo Pharma Co., Ltd. Farmacevtski sestavek, ki vsebuje lurazidon
KR20080024206A (ko) * 2005-06-20 2008-03-17 엘란 파마 인터내셔널 리미티드 아릴-헤테로시클릭 화합물을 함유하는 나노입자형 조절방출 조성물
CN101242813A (zh) * 2005-06-20 2008-08-13 依兰药物国际有限公司 包含芳基-杂环化合物的毫微粒和控制释放组合物
PT2135603E (pt) 2005-11-22 2013-04-03 Orexigen Therapeutics Inc Composições e métodos para aumentar a sensibilidade à insulina
PL1954241T3 (pl) * 2005-11-28 2013-03-29 Orexigen Therapeutics Inc Formulacja zonisamidu o przedłużonym uwalnianiu
PL379569A1 (pl) * 2006-04-28 2007-10-29 Pliva Kraków Zakłady Farmaceutyczne Spółka Akcyjna Sposób wytwarzania kompozycji farmaceutycznej zawierającej substancję aktywną ziprasidone lub jego farmaceutycznie dopuszczalną sól zwiększający rozpuszczalność i biodostępność tego leku, kompozycja farmaceutyczna i zastosowanie hydrofilowych substancji pomocniczych
US8916195B2 (en) 2006-06-05 2014-12-23 Orexigen Therapeutics, Inc. Sustained release formulation of naltrexone
EP1892243A1 (en) * 2006-08-02 2008-02-27 KRKA, tovarna zdravil, d.d., Novo mesto Polymorphic forms of ziprasidone sulphate salts
EP1889844A3 (en) * 2006-08-02 2008-03-05 Krka Polymorphic forms of ziprasidone sulphates
DE602007005402D1 (de) 2006-11-09 2010-04-29 Orexigen Therapeutics Inc Mehrschichtige pharmazeutische formulierungen mit einer schnell auflösenden zwischenschicht
WO2008060964A2 (en) 2006-11-09 2008-05-22 Orexigen Therapeutics, Inc. Unit dosage package and methods for administering weight loss medications
AU2008254957A1 (en) * 2007-05-18 2008-11-27 Scidose Llc Ziprasidone formulations
WO2009032558A2 (en) * 2007-08-31 2009-03-12 Dr. Reddy's Laboratories Ltd. Preparation of ziprasidone hydrochloride monohydrate
US8410268B2 (en) * 2008-03-11 2013-04-02 Alkem Laboratories Limited Process for the preparation of ziprasidone
CA2725930A1 (en) 2008-05-30 2009-12-30 Orexigen Therapeutics, Inc. Methods for treating visceral fat conditions
DE102008045854A1 (de) 2008-09-05 2010-03-11 Tiefenbacher Pharmachemikalien Alfred E. Tiefenbacher Gmbh & Co. Kg Partikel aus Ziprasidone und einem Sprengmittel enthaltende Pharmazeutische Zusammensetzung
JP5732453B2 (ja) 2009-06-25 2015-06-10 アルカーメス ファーマ アイルランド リミテッド Ｎｈ酸性化合物のプロドラッグ
EP2340834A1 (en) 2009-12-30 2011-07-06 Abdi Ibrahim Ilac Sanayi Ve Ticaret Anonim Sirketi Enhanced Solubility of Ziprasidone
ES2762113T3 (es) 2010-01-11 2020-05-22 Nalpropion Pharmaceuticals Inc Métodos de proporcionar terapia de pérdida de peso en pacientes con depresión mayor
IL309564A (en) 2010-02-25 2024-02-01 Pfizer Preparations containing apixaban
WO2011148253A2 (en) 2010-05-25 2011-12-01 Aurobindo Pharma Limited Solid dosage forms of antipsychotics
SI23610A (sl) 2011-01-13 2012-07-31 Diagen@d@o@o Nove adicijske soli ziprasidona postopek za njihovo pripravo in njihova uporaba v terapiji
PL4104824T3 (pl) 2012-06-06 2025-11-12 Nalpropion Pharmaceuticals Llc Kompozycja do zastosowania w sposobie leczenia nadwagi i otyłości u pacjentów z wysokim ryzykiem sercowo-naczyniowym
US10154988B2 (en) 2012-11-14 2018-12-18 The Johns Hopkins University Methods and compositions for treating schizophrenia
AU2019230014B2 (en) 2018-03-05 2024-11-28 Alkermes Pharma Ireland Limited Aripiprazole dosing strategy

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5264446A (en) * 1980-09-09 1993-11-23 Bayer Aktiengesellschaft Solid medicament formulations containing nifedipine, and processes for their preparation
MX173362B (es) * 1987-03-02 1994-02-23 Pfizer Compuestos de piperazinil heterociclicos y procedimiento para su preparacion
US4831031A (en) * 1988-01-22 1989-05-16 Pfizer Inc. Aryl piperazinyl-(C2 or C4) alkylene heterocyclic compounds having neuroleptic activity
US4883795A (en) * 1988-01-22 1989-11-28 Pfizer Inc. Piperazinyl-heterocyclic compounds
DE4141268A1 (de) * 1991-12-14 1993-06-17 Merck Patent Gmbh Pharmazeutische zubereitung
US5206366A (en) * 1992-08-26 1993-04-27 Pfizer Inc. Process for preparing aryl piperazinyl-heterocyclic compounds
US5338846A (en) * 1992-08-26 1994-08-16 Pfizer Inc. Process for preparing aryl piperazinyl-heterocyclic compounds with a piperazine salt
US5312925A (en) * 1992-09-01 1994-05-17 Pfizer Inc. Monohydrate of 5-(2-(4-(1,2-benzisothiazol-3-yl)-1-piperazinyl)-ethyl)-6-chloro-1,3-dihydro-2H-indol-2-one-hydrochloride
US5359068A (en) * 1993-06-28 1994-10-25 Pfizer Inc. Processes and intermediates for the preparation of 5-[2-(4-(benzoisothiazol-3-yl)-piperazin-1-yl)ethyl]-6-chloro-1,3-dihydro-indol-2-one
DK0790236T3 (da) * 1996-02-13 2004-02-23 Pfizer Prolægemidler af 5-(2-(4-(1,2-benzisothiazol-3-yl)-1-piperazinyl)ethyl)-6-chlor-1,3-dihydro-2H-indol-2-on
PT901786E (pt) * 1997-08-11 2007-08-07 Pfizer Prod Inc Disperções farmacêuticas sólidas com biodisponibilidade melhorada

Also Published As

Publication number Publication date
YU27199A (sh) 2002-12-10
KR100338915B1 (ko) 2002-05-30
HUP9901960A2 (hu) 2000-08-28
HN1999000089A (es) 1999-11-03
GT199900080A (es) 2000-11-29
NO992892D0 (no) 1999-06-14
PL195606B1 (pl) 2007-10-31
ZA993938B (en) 2000-12-14
EA002223B1 (ru) 2002-02-28
HUP9901960A3 (en) 2000-09-28
NO992892L (no) 1999-12-16
NO316713B1 (no) 2004-04-13
ATE240732T1 (de) 2003-06-15
SG77243A1 (en) 2000-12-19
DE69908021T2 (de) 2003-11-27
PT965343E (pt) 2003-08-29
SI0965343T1 (en) 2003-10-31
BR9902268A (pt) 2000-05-02
CA2274338A1 (en) 1999-12-15
HRP990193A2 (en) 2000-02-29
EP0965343B1 (en) 2003-05-21
IL130424A (en) 2003-10-31
CA2274338C (en) 2003-04-15
RS49611B (sr) 2007-06-04
HU226487B1 (en) 2009-03-02
CN1307994C (zh) 2007-04-04
AU753820B2 (en) 2002-10-31
CZ212799A3 (cs) 2000-09-13
MA26647A1 (fr) 2004-12-20
AP9901579A0 (en) 1999-06-30
OA11064A (en) 2002-03-13
JP4187423B2 (ja) 2008-11-26
US6150366A (en) 2000-11-21
CN1242987A (zh) 2000-02-02
CO5070579A1 (es) 2001-08-28
IS5079A (is) 1999-12-16
MY121397A (en) 2006-01-28
PA8475601A1 (es) 2000-09-29
CY2003002I1 (el) 2009-11-04
AP1216A (en) 2003-10-19
BG64691B1 (bg) 2005-12-30
EP0965343A3 (en) 2000-02-23
DK0965343T3 (da) 2003-08-04
HU9901960D0 (en) 1999-08-30
ES2197581T3 (es) 2004-01-01
TW590774B (en) 2004-06-11
UA59383C2 (uk) 2003-09-15
AR015553A1 (es) 2001-05-02
BG103489A (en) 2000-07-31
EP0965343A2 (en) 1999-12-22
AU3398399A (en) 1999-12-23
SK286245B6 (sk) 2008-06-06
PL195209B1 (pl) 2007-08-31
KR20000006143A (ko) 2000-01-25
SK76999A3 (en) 2000-12-11
JP2002003492A (ja) 2002-01-09
CZ297954B6 (cs) 2007-05-09
HRP990193B1 (en) 2003-08-31
EA199900467A3 (ru) 2000-04-24
DE69908021D1 (de) 2003-06-26
EA199900467A2 (ru) 1999-12-29
NZ336271A (en) 2000-10-27
PE20000632A1 (es) 2000-07-26
PL333737A1 (en) 1999-12-20
IS2182B (is) 2006-12-15
JP3441676B2 (ja) 2003-09-02
IL130424A0 (en) 2000-06-01
UY25649A1 (es) 2000-02-23
JP2000007566A (ja) 2000-01-11
HK1024184A1 (en) 2000-10-05
TR199901379A2 (xx) 2000-01-21

Similar Documents

Publication Publication Date Title
IS5555A (is) Selekoxib lyfjablöndur
ID30031A (id) Formulasi-formulasi agrokimia
NO20004240D0 (no) Formuleringer
ATE224703T1 (de) Brauseformulierungen
PT1130966E (pt) Formulacoes antiparasitarias
MA24473A1 (fr) Formulations
ATE341990T1 (de) Sigmidoskop
DK0965343T3 (da) Ziprasidonformuleringer
DE59911453D1 (de) Aktivkohlefilter
DE59901560D1 (de) Retrograder tibianagel
ID29635A (id) Formulasi mikrokapsul
DE59907306D1 (de) Fadenchangierung
ID23458A (id) Bentuk sediaan nefazodon
DE69925879D1 (de) Teilchenabbildevorrichtung
DE59906931D1 (de) Exzenterzahnradgetriebe
CY2006006I2 (el) Πρωτεϊνικα σκευασματα
IS6398A (is) Lyfjablöndur
ATE357237T1 (de) Formulierungen enthaltend cefuroxim-axetil
ID27655A (id) Formulasi mikrokapsul
DE59903966D1 (de) Exzenterzahnradgetriebe
NO20005722D0 (no) Brusetilberedninger
DE59901046D1 (de) Methylcyclotetradec-5-en-1-one
DE59807217D1 (de) Nadellager
DE59808995D1 (de) Endomikroskopsystem
DE19842103B4 (de) Stanznietzuführung